about
Targeting TGF-β signaling in cancerA cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactionsTargeting the transforming growth factor-beta signaling pathway in human cancer.Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.Predicting mechanism of biphasic growth factor action on tumor growth using a multi-species model with feedback control.Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancerTregs and rethinking cancer immunotherapy.Roles for growth factors in cancer progression.TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy.TGF-β signaling in breast cancer cell invasion and bone metastasis.Strong impact of TGF-β1 gene polymorphisms on breast cancer risk in Indian women: a case-control and population-based study.Smad phosphoisoform signaling specificity: the right place at the right timeChemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.The Role of Regulatory T Cells in Mesothelioma.Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progressionTGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.Mutations of TGFbeta signaling molecules in human disease.Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.Expression, purification and characterization of BG(E)RII: a novel pan-TGFbeta inhibitorAn anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies.Polygenic susceptibility to breast cancer: current state-of-the-art.Transforming growth factor-beta in breast cancer: too much, too late.Role of emmprin/CD147 in tissue remodeling.The polarization of immune cells in the tumour environment by TGFbeta.Epithelial Plasticity During Human Breast Morphogenesis and Cancer Progression.CLIC4 regulates TGF-β-dependent myofibroblast differentiation to produce a cancer stroma.Stromal Modulators of TGF-β in Cancer.TGF-β autocrine pathway and MAPK signaling promote cell invasiveness and in vivo mammary adenocarcinoma tumor progression.Exploring anti-TGF-β therapies in cancer and fibrosis.Therapeutic modulation of prostate cancer metastasis.Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.Signaling Receptors for TGF-β Family Members.TGF-β1 mediates the radiation response of prostate cancer.Saponins from the roots of Platycodon grandiflorum suppresses TGFβ1-induced epithelial-mesenchymal transition via repression of PI3K/Akt, ERK1/2 and Smad2/3 pathway in human lung carcinoma A549 cells.
P2860
Q27012443-9BA76C22-F0D7-450E-8CE0-16267A01C479Q27653116-4B3DACB8-FFA2-4F1B-A910-BB2FA82B1A41Q33517772-ABAF7800-AA7A-4E1A-ABF4-01BCD64BE258Q33614767-C8DDA3CB-A9AE-4D39-9C77-A6024A37D257Q33690926-3ECA6FF9-1BAF-48D0-9877-6522440D1F17Q33933880-AF4D4FD5-627B-4096-839E-4EAC752CFA1CQ33955028-C3779101-1293-48F0-9AFC-8808D579AC88Q34028615-A7DBB140-3811-4FE0-9401-7E6AA0C9513BQ34343664-856512F3-8C2A-48B5-B0AD-9B6D87BCF33BQ34614133-08A7301A-A296-4251-A881-29BC0560F8ACQ34625147-DE60DD3B-2121-49A6-9B46-A0BDD6489B41Q34705858-2CE1D1A0-9533-4E09-9DFC-D96B832E4E0EQ34804626-D3EA5AD0-2AF6-41D7-A7DD-C8C88959F530Q34985004-6549660C-BB72-4CFE-939E-05B9995A863EQ35022568-0710CB77-B53B-40DF-AF6C-412E92E58C05Q35478946-FCC65846-442C-42BB-98E2-7D0B3CF7D188Q35490960-688E6171-D2B1-4264-82D1-3577CDE8BCF4Q36101238-46C9406A-8EC8-48F7-BE2F-2F5576A0ADEFQ36207817-E299B1F1-1732-4E6D-9877-EE8B499EFAC6Q36339786-EB320CC5-B450-4F4F-84D0-C2A086098525Q36606635-78555EC2-3537-46F9-ACDA-B0A8E6E2ABB9Q36898276-F1A8EA18-836B-4E04-97A8-BDDEE0A8E605Q36953792-77F64794-F250-408C-BA6F-84EFE0EA3106Q36983438-507D1417-C941-471D-8BA2-D3DD77DBD70DQ37048061-AB60B4DB-DFEA-4586-A313-1567B697A61BQ37051022-AA73E594-9E5D-4F10-BBD5-2885A5F3A545Q37062641-13E55C19-1ED1-4877-AC2D-0C23DF56CD23Q37205559-0E216403-913D-4AC8-8E88-01CC812D21A1Q37228554-F4D1A37E-ECAA-4911-8EB3-AFA4FB8CE9AAQ37454364-B63C5C27-3113-4415-9275-CE9205F923D0Q37507345-660D51E9-539E-4147-BCF9-48672B1006DAQ37549392-EC076F22-12DB-42F5-A6DC-B7F86149FD6BQ37628179-F0266624-F0A7-4BFD-B4FC-84B24D25D1CAQ37693902-CAA58D11-97A5-4875-BC46-8110A8003230Q37896073-C1AEF51F-6BA5-4591-9547-547D8850F847Q38182140-0F4B8DF6-7639-40D4-95B9-8A719F983A81Q38866846-F9E6F662-BEEC-465F-96AF-0A32B0FDCC97Q38915720-8E29290F-E5CB-4D4A-ADA1-149BA1DF318CQ38955929-91D9CCBF-A802-4AC6-B5C9-87677BBEC472Q39042970-93DFA048-D93B-430B-AF53-03124F584061
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
TGF beta inhibition for cancer therapy.
@ast
TGF beta inhibition for cancer therapy.
@en
type
label
TGF beta inhibition for cancer therapy.
@ast
TGF beta inhibition for cancer therapy.
@en
prefLabel
TGF beta inhibition for cancer therapy.
@ast
TGF beta inhibition for cancer therapy.
@en
P1476
TGF beta inhibition for cancer therapy.
@en
P2093
Elise F Saunier
Rosemary J Akhurst
P304
P356
10.2174/156800906778742460
P577
2006-11-01T00:00:00Z